Posted on: August 8, 2022
These two BCCDC guidance documents focus on tixagevimab/cilgavimab (EvusheldTM), a long-acting monoclonal antibody, for prevention of COVID-19 in individuals who are expected to have a reduced response to vaccination or who cannot receive a COVID-19 vaccine.
Updates within the Health Care Provider Information document include, what are the current recommendations for tixagevimab/cilgavimab in BC? The Clinical Practice Guide includes revised guidance regarding the use of tixagevimab/cilgavimab for pre-exposure prophylaxis against COVID-19 considering the predominance of the BA 4/5 Variants of Concern in BC.
Health Canada approved tixagevimab/cilgavimab for prevention of COVID-19 in individuals who are immunocompromised and expected to have a reduced response to vaccination or who cannot receive a COVID-19 vaccine.